Ultragenyx Pharmaceutical (RARE) Cash from Financing Activities (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Cash from Financing Activities data on file, last reported at $394.2 million in Q4 2025.

• Cash from Financing Activities for Q4 2025 came in at $394.2 million, up 13285.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $478.0 million (up 19.8% YoY), and the FY2025 annual result was $478.0 million, up 19.8% from the prior year.
• Cash from Financing Activities advanced to $394.2 million in Q4 2025 per RARE's latest filing, from $2000.0 in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $491.9 million in Q3 2022 and troughed at -$722000.0 in Q1 2023.
• A 5-year average of $94.2 million and a median of $11.9 million in 2021 frame the typical range for Cash from Financing Activities.
• On a YoY basis, Cash from Financing Activities climbed as much as 17459.4% in 2023 and fell as far as 144.79% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $85.7 million in 2021, then slumped by 97.8% to $1.9 million in 2022, then jumped by 17459.4% to $330.5 million in 2023, then plunged by 99.11% to $2.9 million in 2024, then jumped by 13285.13% to $394.2 million in 2025.
• Business Quant data shows RARE's Cash from Financing Activities at $394.2 million in Q4 2025, $2000.0 in Q3 2025, and $83.6 million in Q2 2025.